Ben Fidler
Ben Fidler covers how drug development, clinical data and corporate strategy intersect, focusing on what trial readouts and regulatory decisions mean for the biopharma business. He writes for BioPharma Dive on the companies, programs and trends that move the drug industry’s commercial fortunes.
Drug development setbacks and inflection points
Fidler’s core focus is the business impact of drug development results, especially late-stage trials where the stakes are highest.
He regularly reports on Phase 2 and Phase 3 studies, explaining not just whether a drug met its endpoints but what that means for a company’s pipeline and competitive position. In coverage of cancer immunotherapies, such as combinations that fail to improve outcomes in melanoma, he pulls apart the design, endpoints and benchmarks that define success or disappointment. His reporting often centers on inflection points for key programs - pivotal trials, high-profile failures, portfolio resets - and lays out how those moments reshape strategic priorities inside large pharmaceutical companies and biotech developers.
Across these stories he treats clinical data as a business event, translating hazard ratios, response rates and progression-free survival into implications for market share, future investment and partner interest. Negative or mixed results receive as much attention as clear wins, with context on sunk R&D costs, opportunity costs and how management teams respond.
That makes his coverage a useful guide to which experimental drugs are emerging as future franchises and which once-promising assets are becoming write-offs.
Big pharma strategy, partnerships and the deal economy
Alongside trial coverage, Fidler spends significant time on how companies structure their portfolios and partnerships. He writes about licensing deals, research collaborations and acquisitions that reshape pipelines, detailing which assets are changing hands and why the terms matter.
His articles track how big pharma turns to smaller biotechs to fill gaps in oncology, immunology and other high-value areas, and how those biotechs depend on milestone payments and co-development agreements to keep programs moving.
He also follows strategic retrenchment: companies exiting therapeutic areas, shelving once-priority projects, or reorganizing R&D around a narrower set of modalities. When a major drug stumbles, his follow-up coverage often examines how executives attempt to reframe strategy, whether by doubling down in the same category, diversifying into new mechanisms, or looking to deals to rebuild the pipeline.
Financial details are used to ground these shifts - upfront payments, milestones, sales expectations - but his emphasis stays on what decisions say about longer-term direction rather than on short-term market reaction.
Regulatory outcomes and market expectations
Fidler’s reporting frequently tracks drugs through regulatory milestones, from filings and advisory committee meetings to approvals and rejections. He explains how regulators view the same data companies and investors have been debating, and what additional evidence they demand. When an approval comes with restrictive labeling, safety warnings or postmarketing requirements, his stories spell out how that shapes real-world uptake and revenue prospects.
Conversely, when regulators push back, he details the remaining paths forward, such as new trials, different endpoints or narrower target populations.
Across these regulatory stories, he writes with an eye toward expectations.
He highlights when approvals arrive earlier than anticipated, when advisory panels upend consensus, or when safety concerns undermine once-optimistic projections. Comparisons to rival drugs are common, positioning new therapies against established standards of care and other late-stage competitors in the same indication. The result is coverage that situates each decision within a broader landscape of therapeutic options and commercial dynamics.
Explanatory, data-grounded coverage for a business audience
Stylistically, Fidler writes in a straightforward, explanatory mode that assumes readers care about both the science and the balance sheet.
His pieces typically combine concise news leads with several layers of context: how the new findings fit into prior data, what analysts and company executives are saying, and what comes next in development or commercialization. He is careful about overhyping early data, distinguishing between exploratory signals and results robust enough to underpin a filing or a major investment.
Over years on the beat, he has developed a consistent focus on the largest global drugmakers and the smaller developers tied to them through collaborations and licensing deals. His story mix spans quick-turn news on trial readouts and regulatory events, as well as deeper looks at how specific companies manage risk across broad portfolios.
For anyone tracking where the next wave of cancer and other high-impact drugs will come from, and how those bets affect the business fortunes of drug makers, his byline offers steady, analytically minded coverage.
4 more business journalists.
Aaron Karp
Aaron Karp is distinct for connecting airline networks, airport infrastructure, air cargo and policy. He is a senior editor at Air Transport World and has covered aviation since 1999. He has also worked as an editor for cargo-focused and daily aviation publications. His real beat is how airlines and airports respond to growth, regulation, trade conditions, sustainability pressures and technology changes. He covers route planning, network development, airport capacity, infrastructure, cargo flows, trade lanes, safety, air traffic control and future technology. He reports through news, features, opinion pieces, briefings and podcasts. He uses data, executive insight and industry conference reporting to explain market changes. His work links cargo metrics and trade policy to carrier strategy, and connects infrastructure and sustainability decisions to resilience, costs and long-term growth.
Adrienne Roberts
Adrienne Roberts is a business journalist at the Detroit Free Press who covers how policy, regulation and corporate decisions affect Michigan’s cannabis market, jobs, universities and health systems. She has a sustained focus on cannabis taxes, licensing, sales, product rules, consumer safety and local tax revenue. She also reports on unemployment, worker protections, corporate settlements, hiring, higher education, student safety, housing, data centers, health care access and economic forecasts. Roberts joined the Detroit Free Press in 2020 after covering automotive retail, dealers and labor issues for The Wall Street Journal. She explains complex business and regulatory changes with data, legal detail and on-the-ground voices. Her stories focus on practical effects for workers, students, consumers and communities, showing both the numbers and the people behind them.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex DeMarban
Alex DeMarban stands out for tracking major energy projects over time while showing how economic shifts affect local businesses. He reports for the Anchorage Daily News on business, oil and gas, and general assignments. His coverage focuses on Alaska LNG, long-haul energy projects, mining, ports, transportation infrastructure, and the everyday businesses that keep the state running. He examines financing, tax legislation, labor agreements, regulatory approvals, timelines and costs, and connects government and corporate decisions to workers, communities and consumers. He also reports on restaurant closures, grocery stores, breweries, meaderies, parking and trade disputes. His past coverage includes an open-pit mine near the proposed Ambler road, federal port grants and competitive elections. He reports through dollar figures, project details, public records, business owners and affected workers, showing how policy and resource development play out on the ground.